AVTX
Avalo Therapeutics Inc (AVTX)
Healthcare • NASDAQ • $21.57-5.68%
- Symbol
- AVTX
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $21.57
- Daily Change
- -5.68%
- Market Cap
- $1.13B
- Trailing P/E
- N/A
- Forward P/E
- -6.80
- 52W High
- $24.27
- 52W Low
- $3.39
- Analyst Target
- $45.91
- Dividend Yield
- N/A
- Beta
- 0.79
Avalo Therapeutics, Inc., a clinical stage biotechnology company, develops IL-1ß-based treatments for immune-mediated inflammatory diseases in the Unites States. Its lead product includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Wayne, Pennsylvania.
Company websiteResearch AVTX on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.